American Journal of Medical Case Reports
ISSN (Print): 2374-2151 ISSN (Online): 2374-216X Website: Editor-in-chief: Apply for this position
Open Access
Journal Browser
American Journal of Medical Case Reports. 2015, 3(11), 352-358
DOI: 10.12691/ajmcr-3-11-2
Open AccessCase Report

Recurrent Respiratory Papillomatosis Successfully Treated with Gefitinib: A Case Study

Kultan J.1, , Kolek V.1, Fajkosova L.1, Hajduch M.2, Drabek J.2, Tichy T.3 and Tachezy R.4

1Department of Respiratory Medicine, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc

2Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc

3Department of Clinical and Molecular Pathology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc

4National Reference Laboratory for Papillomaviruses, Department of Experimental Virology, Institute of Hematology and Blood Transfusion, Prague

Pub. Date: October 08, 2015

Cite this paper:
Kultan J., Kolek V., Fajkosova L., Hajduch M., Drabek J., Tichy T. and Tachezy R.. Recurrent Respiratory Papillomatosis Successfully Treated with Gefitinib: A Case Study. American Journal of Medical Case Reports. 2015; 3(11):352-358. doi: 10.12691/ajmcr-3-11-2


Background: Recurrent respiratory papillomatosis (RRP) is a rare condition caused by infection of the respiratory tract mucosa with human papillomaviruses. The disease is characterized by a growth of mucosal papillomas, mostly in the laryngeal region and rarely in the more distal parts of the airways. The therapy is often difficult, including both mechanical removal of papillomas and pharmacological therapy. Methods: Presented in the article is a case of regression of papillomatosis in the larynx, trachea and lung parenchyma after administration of gefitinib, an endothelial growth factor receptor inhibitor. The literature review is added into this article to give more information about the etiology, clinical features and treatment. Results: The authors report a case of 42-year-old Caucasian female, recurrent respiratory papillomatosis was diagnosed in her first year of life. Papillomas were primarily diagnosed in the vocal cord region. Both pharmacological and frequently repeated invasive treatment brought no effective solution; by contrast, papillomas spread to the distal airways. A decision to administer gefitinib was made after other treatment modalities had failed. As early as two months later, the therapeutic effect was observed, with regression of both laryngotracheal and pulmonary involvement. Conclusions: Tyrosine kinase inhibitors of epidermal growth factor receptor represent a new treatment possibility for a long-term benefit for patients with recurrent respiratory papillomatosis in whom other modalities failed.

recurrent respiratory papillomatosis (RRP) HPV 6 HPV 11 gefitinib

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


Figure of 4


[1]  Bostrom B, Sidman J, Marker S, Lander T, Drehner D. Gefitinib therapy for life-threatening laryngeal papillomatosis. Arch Otolaryngol Head Neck Surg 2005; 131: 64-67.
[2]  Derkay CS, Wiatrak B. Recurrent respiratory papillomatosis: a review. Laryngoscope 2008; 118: 1236-1247.
[3]  Harman EM, Mosenifar Z, Sharma S, Talavera F, Manning HL, Rice TD. Recurrent respiratory papillomatosis. http// Date last update: Nov 20, 2013. Date last accessed: Aug 14, 2014.
[4]  Tasca RA, Clarke RW. Recurrent respiratory papillomatosis. Arch Dis Child 2006; 91: 689-691.
[5]  Hammoud D, El Haddad B. Squamous cell carcinoma of the lungs arising in recurrent respiratory papillomatosis. Respiratory Medicine CME 2010; 3: 270-272.
[6]  Cook JR, Hill DA, Humphrey PA, Pfeifer JD, El-Mofty SK. Squamous cell carcinoma arising in recurrent respiratory papillomatosis with pulmonary involvement: emerging common pattern of clinical features and human papillomavirus serotype association. Mod Pathol 2000; 13: 914-918.
[7]  Penaloza-Plascencia M, Montoya-Fuentes H, Flores-Martinez SE, Fierro-Velasco FJ, Penaloza-Gonzales JM, Sanchez-Corona J. Molecular identification of 7 human papillomavirus types in recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2000; 126: 1119-1123.
[8]  Stamataki S, Nikolopoulos TP, Korres S, Felekis D, Tzangaroulakis A, Ferekidis E. Juvenile recurrent respiratory papillomatosis: still a mystery disease with difficult management. Head Neck 2007; 29: 155-62.
[9]  Larson DA, Derkay CS. Epidemiology of recurrent respiratory papillomatosis. APMIS 2010; 118: 450-454.
[10]  Armstrong LR, Derkay CS, Reeves WC. Initial results from the national registry for juvenile-onset recurrent respiratory papillomatosis. RRP Task Force. Arch Otolaryngol Head Neck Surg 1999; 125: 743-748.
[11]  Lindeberg H, Elbrond O. Laryngeal papillomas: the epidemiology in a Danish subpopulation 1965-1984. Clin Otolaryngol Allied Sci 1990; 15: 125-131.
[12]  Campisi P, Hawkes M, Simpson K; Canadian Juvenile Onset Respiratory Papillomatosis Working Group. The epidemiology of juvenile onset recurrent respiratory papillomatosis derived from a population level national database. Laryngoscope 2010; 120: 1233-1245.
[13]  Zawadska-Glos L, Jakubowska A, Chmielik M, Bielicka A, Brzewski M. Lower airway papillomatosis in children. Int J Pediatr Otorhinolaryngol 2003; 67: 1117-1121.
[14]  Frauenfelder T, Marincek B, Wildermuth S. Pulmonary spread of recurrent respiratory papillomatosis with malignant transformation: CT findings and airflow simulation. Eu J Radiol Ex 2005; 56: 11-16.
[15]  Batra PS, Hebert RL 2nd, Haines GK 3rd, Holinger LD. Recurrent respiratory papillomatosis with esophageal involvement. Int J Pediatr Otorhinolaryngol 2001; 58: 233-238.
[16]  Kashima H, Mounts P, Leventhal B, Hruban RH. Sites of predilection in recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 1993; 102: 580-583.
[17]  Wiatrak BJ, Wiatrak DW, Broker TR, Lewis L. Recurrent respiratory papillomatosis: a longitudinal study comparing severity associated with human papilloma viral types 6 and 11 and other risk factors in a large pediatric population. Laryngoscope 2004; 114(Suppl.)104: 1-23.
[18]  Balazic J, Masera A, Poljak M. Sudden death caused by laryngeal papillomatosis. Acta Otolaryngol Suppl 1997; 527: 111-113.
[19]  Aggunlu L, Erbas G. Recurrent respiratory papillomatosis with lung involvement. Diagn Interv Radiol 2009; 15: 93-95.
[20]  Buchinsky FJ, Donfack J, Derkay CS, Choi SS, Conley SF, Myer CM III, McClay JE, Campisi P, Wiatrak BJ, Sobol SE, Schweinfurth JM, Tsuji DH, Hu FZ, Rockette HE, Ehrlich GD, Post JC. (2008) Age of child, more than HPV type, is associated with clinical course in recurrent respiratory papillomatosis. PLoS ONE, 3 (5), e2263.
[21]  Silverberg MJ, Thoresen P, Lindeberg H, Grant LA, Shah KV. Condylomata in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstet Gynecol 2003 101: 645-652.
[22]  Shah KV, Stern WF, Shah FK, Bishai D, Kashima HK. Risk factors for juvenile onset recurrent respiratory papillomatosis. Pediatr Infect Dis J 1998 17: 372-376.
[23]  Kiverniti E, Sevdalis N, Rachmanidou-Doran A. A systematic review on recurrent respiratory papillomatosis: clinical effect and duration of benefit of different treatment modalities. Oncol Rev 2010; 4: 35-42
[24]  Shebab N, Sweet BV, Hogikyan ND. Cidofovir for the treatment of recurrent respiratory papillomatosis: a review of the literature. Pharmacotherapy 2005 25: 977-989.
[25]  Limsukon A, Susanto I, Hoo GW, Dubinett SM, Batra RK. Regression of recurrent respiratory papillomatosis with celecoxib and erlotinib combination therapy. Chest 2009; 136: 924-926.
[26]  Loyo M, Pai SI, Netto GJ, Tunkel DE. Aggressive recurrent respiratory papillomatosis in a neonate. Int J Pediatr Otorhinolaryngol 2008; 72: 917-920.
[27]  Zeitels SM, Lopez-Guerra G, Burns JA, Lutch M, Friedman AM, Hillman RE. Microlaryngoscopic and office-based injection of bevacizumab (Avastin) to enhance 532 nm pulsed KTP laser treatment of glottal papillomatosis. Ann Otol Rhinol Laryngol Suppl. 2009 Sep; 201: 1-13.
[28]  Mammas IN, Sourvinos G, Vakonaki E, Giamarelou P, Michael C, Spanidos DA. Novel human papilloma virus (HPV) genotypes in children with recurrent respiratory papillomatosis. Eur J Pediatr 2010; 169: 1017-1021.
[29]  McMurray JS, Connor N, Ford CN. Cidofovir efficacy in recurrent respiratory papillomatosis: a randomized, double-blind, placebo-controlled study. Ann Otol Rhinol Laryngol 2008; 117: 477-483.
[30]  Derkay CS, Smith RJ, McClay J, van Burik JA, Wiatrak BJ, Arnold J, Berger B, Neefe JR. HspE7 treatment of pediatric recurrent respiratory papillomatosis: final results of an open-label trial. Ann Otol Rhinol Laryngol 2005; 114: 730-737.
[31]  Ruan SY, Chen KY, Yang PC. Recurrent respiratory papillomatosis with pulmonary involvement: A case report and review of the literature. Respirology 2009; 14, 137-140.
[32]  Dyrstad SW, Rao KA. Recurrent Respiratory Papillomatosis (RRP)-Juvenile Onset. Clin Med Oncol 2008; 2: 481-486.
[33]  Vambutas A, Di Lorenzo TP, Steinberg BM. Laryngeal papilloma cells have high levels of epidermal growth factor receptor and respond to epidermal growth factor by a decrease in epithelial differentiation. Cancer Res 1993; 53: 910-914.
[34]  Johnston D, Hall H, Di Lorenzo TP, Steinberg BM. Elevation of the epidermal growth factor receptor and dependent signaling in human papillomavirus-infected laryngeal papillomas. Cancer Res 1999; 59: 968-974.
[35]  Steinberg BM, Meade R, Kalinowski SS, Abramson AL. Abnormal differentiation of human papillomavirus-induced laryngeal papillomas. Arch Otolaryngol Head Neck Surg 1990; 116: 1167-1171.